As a result of the acquisition of InGen BioSciences by Exonhit, the new Diaxonhit group benefits from the complementary capabilities derived from both companies’ business models. Its growth is based on the continued development of its distribution activities, and the development of its high added value proprietary innovative diagnostic products.
Diaxonhit owns a broadened and diversified portfolio of proprietary diagnostic products in three specialty areas : transplantation, infectious diseases and cancer diagnosis.
The group is currently marketing two proprietary products, TQS® (Tetanus Quick Stick) for the evaluation of patients’ immune status against tetanus, and BJI Inoplex for the diagnosis of bone joint prosthetic infections. The group also commercializes AlloMap, a molecular test for the surveillance of heart-transplant patients, under an exclusive licence for Europe.
|Size (employees)||110 (est)+35%|
Diaxonhit has 99 Twitter Followers. The number of followers has decreased 2.7% month over month and decreased 3.3% quarter over quarter
Diaxonhit has 15 Facebook Likes. The number of likes has decreased 11.8% month over month and decreased 11.8% quarter over quarter
When was Diaxonhit founded?
Diaxonhit was founded in 1997.
Who are Diaxonhit key executives?
Diaxonhit's key executives are Jean-Michel Carle Grandmougin and Denis Fortier.
How many employees does Diaxonhit have?
Diaxonhit has 110 employees.
Who are Diaxonhit competitors?
Competitors of Diaxonhit include EXACT Sciences, bioMerieux and Cantel Medical.
Where is Diaxonhit headquarters?
Diaxonhit headquarters is located at 65 Boulevard Masséna, Paris.
Where are Diaxonhit offices?
Diaxonhit has offices in Paris and Rockville.
How many offices does Diaxonhit have?
Diaxonhit has 2 offices.